Mirador Capital Partners Invests $3M in Sarepta Therapeutics

Biotech firm's stock sees institutional investment amid ongoing research and development

Mar. 28, 2026 at 11:05am

Got story updates? Submit your updates here. ›

Mirador Capital Partners LP, an investment management firm, has purchased a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a biotechnology company focused on developing precision genetic medicines for rare neuromuscular diseases. Mirador acquired 139,982 shares of Sarepta, valued at approximately $3,012,000, representing about 0.13% ownership of the company.

Why it matters

Sarepta Therapeutics is a prominent player in the rare disease drug development space, with several exon-skipping therapies approved by the FDA for the treatment of Duchenne muscular dystrophy (DMD). This investment by Mirador Capital Partners signals continued institutional interest in Sarepta's pipeline and ongoing research efforts, which could have implications for the company's future growth and development.

The details

According to a recent 13F filing, Mirador Capital Partners purchased the new position in Sarepta Therapeutics during the fourth quarter of the previous fiscal year. The investment firm now owns approximately 0.13% of Sarepta's outstanding shares. Other institutional investors have also added to or reduced their stakes in the company, with some firms increasing their positions and others trimming their holdings.

  • Mirador Capital Partners acquired the Sarepta Therapeutics shares in the fourth quarter of the previous fiscal year.
  • The 13F filing disclosing Mirador's new position in Sarepta was published on March 28, 2026.

The players

Mirador Capital Partners LP

An investment management firm that has purchased a new position in shares of Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.

A biotechnology company focused on developing precision genetic medicines for rare neuromuscular diseases, including several FDA-approved exon-skipping therapies for the treatment of Duchenne muscular dystrophy (DMD).

Got photos? Submit your photos here. ›

The takeaway

This investment by Mirador Capital Partners underscores the continued institutional interest in Sarepta Therapeutics and its efforts to advance treatments for rare genetic disorders like DMD. As Sarepta continues to develop its pipeline and seek regulatory approvals, its stock could see further institutional backing and potentially increased visibility among investors.